A consortium of Chinese and Singapore investors led by Yuan Capital, a Chinese private equity firm, has announced investment of $21million in California biotech firm Eureka Therapeutics.
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on the discovery of fully-human antibody drugs for the treatment of cancer. China's Yuan Capital led the round, with participation from Singapore's Majuven and existing investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.
To see listing and email addresses of investors from China, check the Chinese Investors Directory
More details follows